All GLG News Analyses Filed Under: Ophthalmology

Can Cooper take over the 2 week spherical contact lens market? Can it make a dent in the market share of the industry leader in the silicone hydrogel field? Initial results look good. A definite maybe!

Although the lask procedure as the primary method of keratorefractive surery has been under scrutiny recently it remains the mainstay of refractive surgery.  With a 95% approval it is difficult to critisize its effectiveness. However the 5% patient complaints must be addressed.  The risk of...

The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years:  Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone.  About 1 out of 4 patients that consider lasik are actually good candidates...

I welcome the FDA investigation of LASIK, as thousands of patients are undergoing the elective cosmetic procedure, with some achieving less than optimum results.  Will the study show that LASIK is not safe, or will it show that LASIK is not the real issue, rather that patient selection is...

The media reporting on the FDA hearings on LASIK has generally highlighted unhappy patients' stories and the comments of FDA officials and panel members.  However, The Washington Post's Lauran Neergard has written an insightful article that foresees an important future trend in refractive surgery....

Silicone Hydrgol lenses are the latest technology in the contact lens industry.  Nearly 100% of of my new fits are silicone hydrogel lenses, and the 2 week modality is the most popular wearing schedule. Currenly J&J has the lion's share of the market with their Acuvue Advance and Oasys contact...

I’m not so sure that this is a leap forward for CooperVision.  After long delays for the release of the Biofinity lens, a two-week version has just been released.  The material properties are reportedly “nice”, but certainly scaled back from what was reportedly achieved with Comfilcon...

Any new efficacious glaucoma treatment is welcome and needed, but patient compliance remains a factor.  A single injection treatment that provides IOP reduction for 3 months would greatly improve success in IOP control.  I would, however, like to see a lower target pressure set for the...

A new model of the increasing popular Ex-Press Shunt is quite effective in an early study.  Its is quite safe and effective; and simpler substitute for trabeculectomy.  It could be the first line  in the surgical management of glaucoma.

Alcon (ACL) reported positive interim results for their injectable medication for glaucoma.  A single injection of anecortave acetate  resulted in control of IOP at the three month follow up.  This could be a promising medication for IOP control in glaucoma.